Cytokinetics, Incorporated's next confirmed earnings release is scheduled for November 4, 2026.
| Earnings Date | 11/4/2026 |
As of June 30, 2026, Cytokinetics, Incorporated has 138.76M shares outstanding.
| Shares Outstanding | 138.76M |
As of June 30, 2026, Cytokinetics, Incorporated maintains a current ratio of 6.66, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -732.36, indicating conservative leverage, while an interest coverage ratio of -5.57 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.66 |
| Quick Ratio | 6.56 |
| Debt / Equity | -732.36 |
| Debt / EBITDA | -1.83 |
| Interest Coverage | -5.57 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -56.76, reflecting losses generated across the asset base. The company generates approximately 86,874.62 in revenue per employee across its workforce of 629.25, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -56.76 |
| Revenue Per Employee | 86,874.62 |
| Employee Count | 629.25 |
As of the close on August 31, 2026, Cytokinetics, Incorporated's stock has gained approximately 113.56% over the past 52 weeks.
| 52-Week Price Change | 113.56% |
Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated generated 54.67M in revenue and converted that into -722.20M in net income, yielding earnings per share of -5.80. EBITDA reached -561.73M, while operating income came in at -571.87M.
| Revenue | 54.67M |
| Gross Profit | -116.41M |
| Operating Income | -571.87M |
| Pretax Income | -722.20M |
| Net Income | -722.20M |
| EBITDA | -561.73M |
| EBIT | -571.87M |
| Earnings Per Share (EPS) | -5.80 |
As of June 30, 2026, Cytokinetics, Incorporated holds 941.68M in cash and equivalents against 1.03B in total debt, resulting in a net debt position of 720.44M. Total book value stands at -140.15M, with working capital of 829.69M providing operational flexibility.
| Cash & Cash Equivalents | 941.68M |
| Total Debt | 1.03B |
| Net Debt | 720.44M |
| Equity (Book Value) | -140.15M |
| Book Value Per Share | -1.01 |
| Working Capital | 829.69M |
Cytokinetics, Incorporated produced -448.71M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -20.41M in capital expenditures, free cash flow totaled -469.12M - equivalent to -3.77 per share.
| Operating Cash Flow | -448.71M |
| Capital Expenditures | -20.41M |
| Free Cash Flow | -469.12M |
| FCF Per Share | -3.77 |
Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated posted a gross margin of -212.95, reflecting its pricing power and cost economics. The operating margin of -1,046.12 and net profit margin of -1,321.12 provide insight into operational efficiency.
| Gross Margin | -212.95 |
| Operating Margin | -1,046.12 |
| Pretax Margin | -1,321.12 |
| Profit Margin | -1,321.12 |
| EBITDA Margin | -1,027.58 |
Cytokinetics, Incorporated's most recent stock split took place on June 25, 2013 with a 6:1 split ratio.
| Last Split Date | 6/25/2013 |
| Split Ratio | 6:1 |